#BEGIN_DRUGCARD DB00816

# AHFS_Codes:
12:12.08.12

# ATC_Codes:
R03AB03
R03CB03

# Absorption:
3% (oral bioavailability of 40%)

# Biotransformation:
Hepatic and gastric. The major metabolite, orciprenaline-3-0-sulfate, is produced in the gastrointestinal tract. Orciprenaline is not metabolized by catechol-0-methyltransferase nor have glucuronide conjugates been isolated to date.

# Brand_Mixtures:
Not Available

# Brand_Names:
Alotec
Alupent
Metaprel
Metaproterenol Polistirex
Novasmasol
Prometa

# CAS_Registry_Number:
586-06-1

# ChEBI_ID:
Not Available

# Chemical_Formula:
C11H17NO3

# Chemical_IUPAC_Name:
5-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,3-diol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem]

# Dosage_Forms:
Syrup	Oral

# Drug_Category:
Adrenergic beta-Agonists
Bronchodilator Agents
Sympathomimetics
Tocolytic Agents

# Drug_Interactions:
Acebutolol	Antagonism
Alseroxylon	Increased arterial pressure
Amitriptyline	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of orciprenaline.
Amoxapine	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of orciprenaline.
Atenolol	Antagonism
Betaxolol	Beta-Blockers (Beta1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like orciprenaline. Therapy should be monitored.
Bevantolol	Antagonism
Bisoprolol	Antagonism
Carteolol	Antagonism
Carvedilol	Antagonism
Clomipramine	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of orciprenaline.
Deserpidine	Increased arterial pressure
Desipramine	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of orciprenaline.
Doxepin	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of orciprenaline.
Esmolol	Antagonism
Imipramine	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of orciprenaline.
Isocarboxazid	Increased arterial pressure
Labetalol	Antagonism
Linezolid	Possible increase of arterial pressure
Methyldopa	Increased arterial pressure
Metoprolol	Antagonism
Midodrine	Increased arterial pressure
Moclobemide	Moclobemide increases the sympathomimetic effect of orciprenaline.
Nadolol	Antagonism
Nortriptyline	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of orciprenaline.
Oxprenolol	Antagonism
Pargyline	Increased arterial pressure
Penbutolol	Antagonism
Phenelzine	Increased arterial pressure
Pindolol	Antagonism
Practolol	Antagonism
Propranolol	Antagonism
Protriptyline	The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of orciprenaline.
Rasagiline	Increased arterial pressure
Reserpine	Increased arterial pressure
Sotalol	Antagonism
Timolol	Antagonism
Tranylcypromine	Increased arterial pressure
Trimipramine	The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of orciprenaline.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
9.7mg/L

# Food_Interactions:
Avoid high doses of caffeine.
Take without regard to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Orciprenaline

# HET_ID:
Not Available

# Half_Life:
6 hours

# InChI_Identifier:
InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-9(13)5-10(14)4-8/h3-5,7,11-15H,6H2,1-2H3

# InChI_Key:
InChIKey=LMOINURANNBYCM-UHFFFAOYSA-N

# Indication:
For the treatment of bronchospasm, chronic bronchitis, asthma, and emphysema.

# KEGG_Compound_ID:
C07144

# KEGG_Drug_ID:
D00685

# LIMS_Drug_ID:
816

# Mechanism_Of_Action:
Orciprenaline is a moderately selective beta(2)-adrenergic agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on alpha-adrenergic receptors. Intracellularly, the actions of orciprenaline are mediated by cAMP, the production of which is augmented by beta stimulation. The drug is believed to work by activating adenylate cyclase, the enzyme responsible for producing the cellular mediator cAMP.

# Melting_Point:
100 Â°C

# Molecular_Weight_Avg:
211.2576

# Molecular_Weight_Mono:
211.120843415

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA450390

# Pharmacology:
Orciprenaline (also known as metaproterenol), a synthetic amine, is structurally and pharmacologically similar to isoproterenol. Orciprenaline is used exclusively as a bronchodilator. The pharmacologic effects of beta adrenergic agonist drugs, such as orciprenaline, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

# Predicted_LogP_Hydrophobicity:
-0.32

# Predicted_LogS:
-1.5

# Predicted_Water_Solubility:
6.92e+00 g/l

# Primary_Accession_No:
DB00816

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
4086

# PubChem_Substance_ID:
46504464

# RxList_Link:
http://www.rxlist.com/cgi/generic2/metaproterenol.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00210

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(C)NCC(O)C1=CC(O)=CC(O)=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Metaproterenol
Metaproterenol Sulfate
Orciprenalina [INN-Spanish]
Orciprenaline Sulfate
Orciprenalinum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include angina, hypertension or hypotension, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise and insomnia. LD<sub>50</sub>=42 mg/kg (orally in rat).

# Update_Date:
2013-02-08 16:19:39 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Orciprenaline

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10490901	Kimura M, Ogihara M: Stimulation by transforming growth factor-alpha of DNA synthesis and proliferation of adult rat hepatocytes in primary cultures: modulation by alpha- and beta-adrenoceptor agonists. J Pharmacol Exp Ther. 1999 Oct;291(1):171-80.
10973730	Hu DN, Woodward DF, McCormick SA: Influence of autonomic neurotransmitters on human uveal melanocytes in vitro. Exp Eye Res. 2000 Sep;71(3):217-24.
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
2870555	Fitch KD: The use of anti-asthmatic drugs. Do they affect sports performance? Sports Med. 1986 Mar-Apr;3(2):136-50.
3168573	Gelmont DM, Balmes JR, Yee A: Hypokalemia induced by inhaled bronchodilators. Chest. 1988 Oct;94(4):763-6.
8760245	Singh H, Linas S: Beta 2-adrenergic function in cultured rat proximal tubule epithelial cells. Am J Physiol. 1996 Jul;271(1 Pt 2):F71-7.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
ADRB2

# Drug_Target_1_GenBank_ID_Gene:
Y00106

# Drug_Target_1_GenBank_ID_Protein:
29371

# Drug_Target_1_GeneCard_ID:
ADRB2

# Drug_Target_1_Gene_Name:
ADRB2

# Drug_Target_1_Gene_Sequence:
>1242 bp
ATGGGGCAACCCGGGAACGGCAGCGCCTTCTTGCTGGCACCCAATAGAAGCCATGCGCCG
GACCACGACGTCACGCAGCAAAGGGACGAGGTGTGGGTGGTGGGCATGGGCATCGTCATG
TCTCTCATCGTCCTGGCCATCGTGTTTGGCAATGTGCTGGTCATCACAGCCATTGCCAAG
TTCGAGCGTCTGCAGACGGTCACCAACTACTTCATCACTTCACTGGCCTGTGCTGATCTG
GTCATGGGCCTGGCAGTGGTGCCCTTTGGGGCCGCCCATATTCTTATGAAAATGTGGACT
TTTGGCAACTTCTGGTGCGAGTTTTGGACTTCCATTGATGTGCTGTGCGTCACGGCCAGC
ATTGAGACCCTGTGCGTGATCGCAGTGGATCGCTACTTTGCCATTACTTCACCTTTCAAG
TACCAGAGCCTGCTGACCAAGAATAAGGCCCGGGTGATCATTCTGATGGTGTGGATTGTG
TCAGGCCTTACCTCCTTCTTGCCCATTCAGATGCACTGGTACCGGGCCACCCACCAGGAA
GCCATCAACTGCTATGCCAATGAGACCTGCTGTGACTTCTTCACGAACCAAGCCTATGCC
ATTGCCTCTTCCATCGTGTCCTTCTACGTTCCCCTGGTGATCATGGTCTTCGTCTACTCC
AGGGTCTTTCAGGAGGCCAAAAGGCAGCTCCAGAAGATTGACAAATCTGAGGGCCGCTTC
CATGTCCAGAACCTTAGCCAGGTGGAGCAGGATGGGCGGACGGGGCATGGACTCCGCAGA
TCTTCCAAGTTCTGCTTGAAGGAGCACAAAGCCCTCAAGACGTTAGGCATCATCATGGGC
ACTTTCACCCTCTGCTGGCTGCCCTTCTTCATCGTTAACATTGTGCATGTGATCCAGGAT
AACCTCATCCGTAAGGAAGTTTACATCCTCCTAAATTGGATAGGCTATGTCAATTCTGGT
TTCAATCCCCTTATCTACTGCCGGAGCCCAGATTTCAGGATTGCCTTCCAGGAGCTTCTG
TGCCTGCGCAGGTCTTCTTTGAAGGCCTATGGGAATGGCTACTCCAGCAACGGCAACACA
GGGGAGCAGAGTGGATATCACGTGGAACAGGAGAAAGAAAATAAACTGCTGTGTGAAGAC
CTCCCAGGCACGGAAGACTTTGTGGGCCATCAAGGTACTGTGCCTAGCGATAACATTGAT
TCACAAGGGAGGAATTGTAGTACAAATGACTCACTGCTGTAA

# Drug_Target_1_General_Function:
Involved in beta2-adrenergic receptor activity

# Drug_Target_1_General_References:
10499588	Cao TT, Deacon HW, Reczek D, Bretscher A, von Zastrow M: A kinase-regulated PDZ-domain interaction controls endocytic sorting of the beta2-adrenergic receptor. Nature. 1999 Sep 16;401(6750):286-90.
11146000	Moffett S, Rousseau G, Lagace M, Bouvier M: The palmitoylation state of the beta(2)-adrenergic receptor regulates the synergistic action of cyclic AMP-dependent protein kinase and beta-adrenergic receptor kinase involved in its phosphorylation and desensitization. J Neurochem. 2001 Jan;76(1):269-79.
2540197	O'Dowd BF, Hnatowich M, Caron MG, Lefkowitz RJ, Bouvier M: Palmitoylation of the human beta 2-adrenergic receptor. Mutation of Cys341 in the carboxyl tail leads to an uncoupled nonpalmitoylated form of the receptor. J Biol Chem. 1989 May 5;264(13):7564-9.
2823249	Emorine LJ, Marullo S, Delavier-Klutchko C, Kaveri SV, Durieu-Trautmann O, Strosberg AD: Structure of the gene for human beta 2-adrenergic receptor: expression and promoter characterization. Proc Natl Acad Sci U S A. 1987 Oct;84(20):6995-9.
2831218	Chung FZ, Wang CD, Potter PC, Venter JC, Fraser CM: Site-directed mutagenesis and continuous expression of human beta-adrenergic receptors. Identification of a conserved aspartate residue involved in agonist binding and receptor activation. J Biol Chem. 1988 Mar 25;263(9):4052-5.
3025863	Kobilka BK, Dixon RA, Frielle T, Dohlman HG, Bolanowski MA, Sigal IS, Yang-Feng TL, Francke U, Caron MG, Lefkowitz RJ: cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci U S A. 1987 Jan;84(1):46-50.
3026848	Chung FZ, Lentes KU, Gocayne J, Fitzgerald M, Robinson D, Kerlavage AR, Fraser CM, Venter JC: Cloning and sequence analysis of the human brain beta-adrenergic receptor. Evolutionary relationship to rodent and avian beta-receptors and porcine muscarinic receptors. FEBS Lett. 1987 Jan 26;211(2):200-6.
3033609	Schofield PR, Rhee LM, Peralta EG: Primary structure of the human beta-adrenergic receptor gene. Nucleic Acids Res. 1987 Apr 24;15(8):3636.
3034889	Kobilka BK, Frielle T, Dohlman HG, Bolanowski MA, Dixon RA, Keller P, Caron MG, Lefkowitz RJ: Delineation of the intronless nature of the genes for the human and hamster beta 2-adrenergic receptor and their putative promoter regions. J Biol Chem. 1987 May 25;262(15):7321-7.
7706471	Turki J, Pak J, Green SA, Martin RJ, Liggett SB: Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest. 1995 Apr;95(4):1635-41.
7915137	Green SA, Turki J, Innis M, Liggett SB: Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994 Aug 16;33(32):9414-9.
8383511	Reihsaus E, Innis M, MacIntyre N, Liggett SB: Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol. 1993 Mar;8(3):334-9.

# Drug_Target_1_HGNC_ID:
HGNC:286

# Drug_Target_1_HPRD_ID:
00187

# Drug_Target_1_ID:
766

# Drug_Target_1_Locus:
5q31-q32

# Drug_Target_1_Molecular_Weight:
46557

# Drug_Target_1_Name:
Beta-2 adrenergic receptor

# Drug_Target_1_Number_of_Residues:
413

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Amlodipine Pathway	SMP00376
Benazepril Pathway	SMP00145
Captopril Pathway	SMP00146
Cilazapril Pathway	SMP00147
Diltiazem Pathway	SMP00359
Enalapril Pathway	SMP00148
Felodipine Pathway	SMP00377
Fosinopril Pathway	SMP00149
Isradipine Pathway	SMP00378
Lisinopril Pathway	SMP00150
Moexipril Pathway	SMP00151
Nifedipine Pathway	SMP00379
Nimodipine Pathway	SMP00380
Nisoldipine Pathway	SMP00381
Nitrendipine Pathway	SMP00382
Perindopril Pathway	SMP00152
Quinapril Pathway	SMP00153
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Trandolapril Pathway	SMP00157
Verapamil Pathway	SMP00375

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Beta-2 adrenergic receptor
MGQPGNGSAFLLAPNRSHAPDHDVTQQRDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAK
FERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTAS
IETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQE
AINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSEGRF
HVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQD
NLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNT
GEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Beta-adrenergic receptors mediate the catecholamine- induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine

# Drug_Target_1_SwissProt_ID:
P07550

# Drug_Target_1_SwissProt_Name:
ADRB2_HUMAN

# Drug_Target_1_Synonyms:
Beta-2 adrenoceptor
Beta-2 adrenoreceptor

# Drug_Target_1_Theoretical_pI:
7.44

# Drug_Target_1_Transmembrane_Regions:
35-58
72-95
107-129
151-174
197-220
275-298
306-329

#END_DRUGCARD DB00816
